Health
Biotechnology
Pharmaceutical
Ionis Pharmaceuticals
$70.549876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.
$70.54
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
+$3.13 (4.64%) As of 2:56 PM EDT today
+$3.13 (4.64%) Today
Why Robinhood?
You can buy or sell IONS and other stocks, options, ETFs, and crypto commission-free!
About IONS
Ionis Pharmaceuticals, Inc. engages in the development and commercialization of human therapeutic drugs using antisense technology. It operates through the Ionis Core and Akcea Therapeutics segments. Read More The Ionis Core segment exploits a novel drug discovery platform to generate a pipeline of drugs. The Akcea Therapeutics segment develops and commercializes drugs for cardiometabolic diseases. The company was founded by Stanley T. Crooke, David J. Ecker, Christopher K. Mirabelli and Brett P. Monia in 1989 and is headquartered in Carlsbad, CA.
Employees
737
Headquarters
Carlsbad, California
Founded
1989
Market Cap
9.41B
Price-Earnings Ratio
27.20
Dividend Yield
0.00
Average Volume
861.82K
High Today
$70.83
Low Today
$67.31
Open Price
$67.31
Volume
893.50K
52 Week High
$86.58
52 Week Low
$41.25
Collections
Health
Biotechnology
Pharmaceutical
Therapy
Technology
Price Paid on Robinhood
16% Higher
Right Now
52 Week Low
$41.25
Average Price Paid
$60.60
52 Week High
$86.58
Analyst Ratings
24%
of 17 ratings
Buy
24%
Hold
59%
Sell
18%
IONS Earnings
-$0.17
$0.09
$0.36
$0.62
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Q2 2019
Estimated
—
Actual
Expected Aug 6, Pre-Market